News and Trends 23 Feb 2018 Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […] February 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B Sanofi will acquire Ablynx and get its hands on the biotech’s exciting Nanobody technology just months after the biotech joined Europe’s billion-euro biotech club. Despite rejecting the advances of Novo Nordisk earlier this month, a decision that led to a 60% jump in Ablynx’s stock, the biotech has voted unanimously in favor of being acquired Sanofi. Sanofi has […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Dec 2017 The Biggest Biotech News of 2017: What Happened This Year? Still catching up on news? We’ve picked out the most exciting things that happened besides clinical results and finance. Here’s the biggest biotech news of 2017. We’ve been recapping the year with the most stellar biotechs, most heartening clinical successes and most disappointing failures in biotech. But what else happened this year? There’s more news […] December 27, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […] December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of the year, Regeneron and Sanofi are still committed to pushing through a number of candidates. One of these, cemiplimab, is a programmed cell death protein-1 (PD-1) checkpoint […] December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2017 An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up Sanofi’s rapid-action insulin, Admelog, will be the first “follow-on” insulin product on the market to help diabetics manage their blood sugar at mealtimes. Sanofi has announced the FDA approval of Admelog, the first “follow-on” mealtime insulin available to type 1 and type 2 diabetics. This gave the company’s stock price a boost of 1.1% this morning, which is […] December 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2017 The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […] December 5, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world. Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by […] October 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 German Researchers’ Algorithm Can Predict New Targets for Existing Drugs An algorithm based on the brain’s self-organizing capacity has been developed in Germany that could combat the rising costs of drug development. A team at TU Dresden has pioneered an algorithm that exploits the self-organization of the brain to predict new drug targets, without the need for extra biological or molecular information. The study, published in Briefings […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2017 Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains Sanofi, in collaboration with the US National Institute of Health, is developing an antibody HIV treatment that can kill 99% of strains. Human immunodeficiency virus (HIV) is notoriously difficult to treat as it mutates so quickly. Some patients develop ‘broadly neutralizing antibodies’ that attack fundamental parts of the virus, and are therefore very powerful tools. Researchers […] September 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email